Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25339310 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AJAK2JAK1 | |
| SCHEMBL13963235 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AJAK2JAK1 | |
| SCHEMBL13963237 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AJAK2JAK1 | |
| SCHEMBL13963234 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AJAK2JAK1 | |
| SCHEMBL32671859 | 0.92 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AJAK2JAK1 | |
| SCHEMBL30368581 | 0.92 | SIGMAR1 (0.52) | SMN1; SMN2NPC1RAB9AJAK2JAK1 | |
| SCHEMBL28693156 | 0.91 | SIGMAR1 (0.44) | SMN1; SMN2NPC1RAB9AJAK2JAK1 | |
| SCHEMBL13569652 | 0.91 | SIGMAR1 (0.44) | SMN1; SMN2NPC1RAB9AJAK2JAK1 | |
| SCHEMBL31520646 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AJAK2JAK1 | |
| SCHEMBL13243625 | 0.85 | USP30 (0.57) | SMN1; SMN2NPC1RAB9AJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-1664026-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7465746-B2 | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP | MERCK & CO., INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465746-B2 | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP | MERCK & CO., INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080207693-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| US-20080207693-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| US-20070225499-A1 | Process for the Preparation of 2,2-Disubstituted Pyrroles | MERCK & CO., INC. | 2007-09-27 | — | — | US | disclosed |
| US-20060234984-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. | 2006-10-19 | — | — | US | disclosed |
| US-20050038074-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J (US) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225499-A1 | Process for the Preparation of 2,2-Disubstituted Pyrroles | KIF5B, KIF5A, KIF5C | SMN1; SMN2 1287/4885NPC1 2288/4885RAB9A 2170/4885 |
| US-20060234984-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | KIF5B, KIF2C, KIF5C | SMN1; SMN2 1979/4885NPC1 1011/4885RAB9A 1615/4885 |
| US-20050038074-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | SMN1; SMN2 1987/4885NPC1 1291/4885RAB9A 1418/4885 |
| US-20080207693-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF23 | SMN1; SMN2 2073/4885NPC1 1071/4885RAB9A 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.